Back to top
more

Array Technologies (ARRY)

(Delayed Data from NSDQ)

$5.91 USD

5.91
6,255,864

-0.09 (-1.50%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $5.90 -0.01 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 246)

Industry: Solar

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Tinder Gold Drive Match Group's (MTCH) Q1 Earnings?

by Zacks Equity Research

Match Group's (MTCH) first-quarter 2018 earnings to benefit from steady market traction of apps like Tinder, which are driving higher subscriber growth.

    Zacks Equity Research

    Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up?

    by Zacks Equity Research

    Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.

      Zacks Equity Research

      What's in Store for Celldex (CLDX) This Earnings Season?

      by Zacks Equity Research

      With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.

        Zacks Equity Research

        What's in the Cards for Geron (GERN) This Earnings Season?

        by Zacks Equity Research

        With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

          Zacks Equity Research

          What's in the Cards for Merrimack (MACK) in Q1 Earnings?

          by Zacks Equity Research

          Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.

            Zacks Equity Research

            Options Traders Expect Huge Moves in Array BioPharma (ARRY) Stock

            by Zacks Equity Research

            Array BioPharma (ARRY) needs investors to pay close attention to the stock based on moves in the options market lately.

              Zacks Equity Research

              Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget

              by Zacks Equity Research

              Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget

                Zacks Equity Research

                Array's Melanoma Combo Shows Positive Overall Survival Data

                by Zacks Equity Research

                Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.

                  Zacks Equity Research

                  Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session

                  by Zacks Equity Research

                  Array BioPharma (ARRY) shares rose nearly 10% in the last trading session, amid huge volumes.

                    Zacks Equity Research

                    Are Options Traders Betting on a Big Move in Array BioPharma (ARRY) Stock?

                    by Zacks Equity Research

                    Investors need to pay close attention to Array BioPharma (ARRY) stock based on the movements in the options market lately.

                      Zacks Equity Research

                      Is the Options Market Predicting a Spike in Array BioPharma (ARRY) Stock?

                      by Zacks Equity Research

                      Investors need to pay close attention to Array BioPharma (ARRY) stock based on the movements in the options market lately.

                        Zacks Equity Research

                        Array's NDAs for Melanoma Combo Accepted for Review by FDA

                        by Zacks Equity Research

                        Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.

                          Zacks Equity Research

                          Array BioPharma (ARRY) Looks Good: Stock Adds 5.9% in Session

                          by Zacks Equity Research

                          Array BioPharma (ARRY) shares rose nearly 6% in the last trading session, amid huge volumes.

                            Zacks Equity Research

                            New Strong Sell Stocks for July 20th

                            by Zacks Equity Research

                            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                              Zacks Equity Research

                              Implied Volatility Surging for Array BioPharma Inc. (ARRY) Stock Options

                              by Zacks Equity Research

                              Implied Volatility Surging for Array BioPharma Inc. (ARRY) Stock makes it lucrative to Option traders.

                                Zacks Equity Research

                                Array (ARRY) Submits NDA for Melanoma Combination Therapy

                                by Zacks Equity Research

                                Array BioPharma (ARRY) announced that it has submitted two new drug applications (NDAs) to FDA, seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

                                  Zacks Equity Research

                                  Are Options Traders Betting on a Big Move in Array BioPharma (ARRY) Stock?

                                  by Zacks Equity Research

                                  Investors in Array BioPharma Inc. (ARRY) need to pay close attention to the stock based on moves in the options market lately.

                                    Zacks Equity Research

                                    Bristol-Myers Partners Array to Investigate Cancer Candidate

                                    by Zacks Equity Research

                                    Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.

                                      Zacks Equity Research

                                      Do Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't?

                                      by Zacks Equity Research

                                      Investors in Array BioPharma Inc. (ARRY) need to pay close attention to the stock based on moves in the options market lately.

                                        Zacks Equity Research

                                        Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down

                                        by Zacks Equity Research

                                        Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.

                                          Zacks Equity Research

                                          Will Array BioPharma (ARRY) Continue to Surge Higher?

                                          by Zacks Equity Research

                                          As of late, it has definitely been a great time to be an investor in Array BioPharma Inc. (ARRY)

                                            Zacks Equity Research

                                            Zacks Investment Ideas feature highlights: Array BioPharma, BHP Billition, MSC Industrial Direct, Rio Tinto and Vantiv

                                            by Zacks Equity Research

                                            Zacks Investment Ideas feature highlights: Array BioPharma, BHP Billition, MSC Industrial Direct, Rio Tinto and Vantiv

                                              Zacks Equity Research

                                              Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session

                                              by Zacks Equity Research

                                              Array BioPharma Inc. (ARRY) shares rose over 7% in the last trading session.